Drug Information Association Logo

DIA to Host Webinar to Provide Insight into Optimizing Development of New Alzheimers Therapies and Early Diagnosis

WASHINGTON — May 2, 2013

DIA today announced the second in its four-part Solution Provider educational webinar series held in cooperation with ICON plc. On May 21, DIA will host: Biomarker Strategies for More Efficient Early-Phase Drug Development in Alzheimer’s Disease.

ICON is the first to collaborate with DIA’s newly-created Solution Provider Webinar Program. DIA’s educational collaboration with ICON will bring together leading scientists and thought leaders from the biopharma industry who will host four webinars throughout 2013. The webinars are free to DIA customers and will feature topics including oncology, strategies for late phase development, biomarkers and technology as an enabler of clinical development services.

Susan Cantrell, Director, North America at DIA said, “We are excited to host what will prove to be an insightful and in depth discussion on early phase drug development in Alzheimer’s disease.  We take enormous pride in facilitating discussions that lay the foundation for more effective and efficient healthcare globally.  With the high-level presenters participating in this webinar, the transfer of knowledge will be truly second to none”

Prof. Dr. Klaudius Siegfried, Vice President & Global CNS Therapeutic Area Leader, ICON plc said, “The advancement of biomarkers for Alzheimer's disease is essential to improve early diagnosis, accelerate the development of new therapies, and to identify patients likely to respond to treatment. ICON is pleased to work with an association as respected as DIA to present the industry insights of our expert panelists, discussing innovative solutions to overcome the drug development challenges in the most common form of dementia affecting millions of individuals worldwide.”





ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.

ABOUT ICON PLC: ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently, operates from 79 locations in 37 countries and has approximately 10,200 employees. Further information is available at www.iconplc.com